Improving Vascular Access Outcomes Using an Innovative Subcutaneous Access System

ANNA Annual National Meeting - Dinner Symposium
May 2002
Access to this symposium is free, but you need to register for the FREE ZONE of HDCN and choose a loginID and password.
Hemodialysis Catheters and Subcutaneous Access Devices: What are the Differences?
Christine Chmielewski, MS, CRNP, CS, CNN.
Moderator: Jean M. Nardini, MSN, RN, CNN.
Subcutaneous Dialysis Access: A Nurse's Experience
Tammy Hlad, RN.
Subcutaneous Vascular Access: A Patient's Experience
Mr. Carl Nettleton



After participating in this program, the learner should be able to:
  1. Describe recent trends in the use of HD catheters and complications associated with their use.
  2. Verbalize how the design, mechanism, and operation of the access device effects cannulation.
  3. Provide an overview of clinical outcomes reported to date with the new access system.
  4. Explain pre and post access care and appropriate nursing interventions.
Moderator: Jean M. Nardini, MSN, RN CNN
Director of Patient Care Services
Renal Division
Massachusetts General Hospital
Boston, MA

Christine M. Chmielewski, MS, CRNP, CS, CNN
Nurse Practitioner
Edward J. Filippone, MD, PC & Associates
Philadelphia, PA

Tammy Hlad, RN
Area Clinic Manager
Fresenius Medical Care
Moore, OK

Carl Nettleton
Dialysis patient
Gretna, LA

This educational activity is supported by an educational grant from Vasca Inc. This activity has been planned and produced in accordance with CE Guidelines and Policies. This educational activity is based on an official ANNA satellite symposium, but the program was not planned by the ANNA Program Committee.
The series of talks is approved for 1.7 CE Contact Hours by the American Nephrology Nurses' Association (ANNA) .
Date of Original Release: August 17, 2002
CE Credit Eligible Through: August 17, 2003
CE Credit Hours/Completion Time: 1.7
Target Audiences: Nephrology Nurses and Technicians.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.

STATEMENT OF NEED :
Adequate care of end-stage renal disease (ESRD) hemodialysis dependent patient requires constant attention to the need to maintain vascular access patency. An ideal access delivers a flow rate adequate for the dialysis prescription, has a long use-life, and has a low rate of complications (eg, infection, stenosis, thrombosis, aneurysm, and limb ischemia). Apart from perhaps an AV fistule, no current access type fulfills all of these criteria.

ACCREDITATION STATEMENT:
This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA, East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738. This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.

The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.

DESIGNATION STATEMENT:
The American Nephrology Nurses' Association approves this educational activity for continuing education credits (Contact Hours) for nurses.

FACULTY DISCLOSURE STATEMENTS :
The American Nephrology Nurses' Association, as well as HDCN have conflict of interest policies that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Ms. Nardini has nothing to disclose.

Ms. Chmielewski has nothing to disclose.

Ms. Hlad has nothing to disclose.

Mr. Nettleton is on the Patient Advisory Board for Vasca.

DISCLOSURE OF UNLABELED USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. Neither the American Nephrology Nurses' Association nor HDCN recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

DISCLAIMER :
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity is supported by an educational grant from Vasca Inc.
This activity has been planned and produced in accordance with CE Guidelines and Policies.
This educational activity is based on an official ANNA satellite symposium, but the program was not planned by the ANNA Program Committee.